The Order of Ministry of
Health of Ukraine
28.05.19 № 1186
For medical use
active substance: voglibose;
1 tablet contains voglibose 0.2 mg or 0.3 mg;
excipients: lactose monohydrate, maize starch, povidone K30, sodium starch glycolate (type A), colloidal anhydrous silica, magnesium stearate.
Pharmaceutical form: Tablets.
Main physicochemical properties:
Voxid, tablets 0.2 mg: white round flat tablets with bevelled edges, embossed with "K" on one side and a score line on the other side;
Voxid, tablets 0.3 mg: white round flat tablets with bevelled edges, embossed with "K" on one side.
Hypoglycemic agents, excluding insulins. Code АТС A10B F03.
Voglibose is an oral hypoglycemic agent, a competitive inhibitor of intestinal alpha-glucosidases (hydrolase enzymes), which are involved in the cleavage of di-, oligo- and polysaccharides. The inhibition of α-glucosidase activity reduces the cleavage of complex carbohydrates and glucose absorption, resulting in a reduction in postprandial blood glucose level (postprandial hyperglycemia).
Voglibose does not affect the activity of β-glucosidase.
Voglibose is slowly and poorly absorbed and rapidly excreted in feces. Currently, no metabolites of the substance have been identified in the human blood and urine. The animal studies have shown that voglibose penetrates through the placenta and into breast milk.